Skip to content
Farxiga, Forxiga(dapagliflozin)
Ebymect, Edistride, Farxiga, Forxiga, Qtern, Qternmet, Qtrilmet, Xigduo (dapagliflozin) is a small molecule pharmaceutical. Dapagliflozin was first approved as Forxiga on 2012-11-11. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat chronic renal insufficiency, diabetes mellitus, glucose metabolism disorders, heart failure, and metabolic diseases amongst others. It is known to target sodium/glucose cotransporter 1 and sodium/glucose cotransporter 2.
Download report
Favorite
COVID-19
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
cardiovascular diseasesD002318
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Farxiga (generic drugs available since 2022-02-22)
Combinations
Qtern, Xigduo (discontinued: Qternmet)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dapagliflozin
Tradename
Company
Number
Date
Products
FARXIGAAstraZenecaN-202293 RX2014-01-08
2 products, RLD, RS
Dapagliflozin
+
Metformin hydrochloride
Tradename
Company
Number
Date
Products
XIGDUO XRAstraZenecaN-205649 RX2014-10-29
5 products, RLD, RS
Dapagliflozin
+
Metformin hydrochloride
+
Saxagliptin hydrochloride
Tradename
Company
Number
Date
Products
QTERNMET XRAstraZenecaN-210874 DISCN2019-05-02
4 products, RLD
Hide discontinued
Dapagliflozin
+
Saxagliptin hydrochloride
Tradename
Company
Number
Date
Products
QTERNAstraZenecaN-209091 RX2017-02-27
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
farxigaNew Drug Application2023-05-08
qternNew Drug Application2020-01-24
xigduoNew Drug Application2020-01-21
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
type 2 diabetes mellitusEFO_0001360D003924E11
Agency Specific
FDA
EMA
Expiration
Code
DAPAGLIFLOZIN, FARXIGA, ASTRAZENECA AB
2024-04-30I-857
2023-05-05I-834
Patent Expiration
Patent
Expires
Flag
FDA Information
Dapagliflozin, Farxiga, Astrazeneca Ab
109738362040-03-09U-3127
86859342030-05-26U-1522
87216152030-01-18DP
79195982029-12-16DP
78515022028-08-19DP
82217862028-03-21DP
83619722028-03-21U-493, U-1976, U-1977, U-2139
87162512028-03-21DP
85016982027-06-20DPU-493, U-1976, U-1977
83296482026-08-18U-2139, U-2212, U-2213
89068512026-08-18U-2139
65151172025-10-04DS, DPU-493, U-2139
74562542025-06-30DPU-2139
84316852025-04-13DPU-2139
84611052025-04-13DPU-2139
92380762024-04-15DPU-2139
Dapagliflozin / Metformin Hydrochloride, Xigduo Xr, Astrazeneca Ab
96160282030-11-12DP
Dapagliflozin / Metformin Hydrochloride / Saxagliptin Hydrochloride, Qternmet Xr, Astrazeneca Ab
86287992025-07-13DP
RE441862023-07-31DS, DPU-493
ATC Codes
A: Alimentary tract and metabolism drugs
A10: Drugs used in diabetes
A10B: Blood glucose lowering drugs, excl. insulins
A10BD: Combinations of oral blood glucose lowering drugs
A10BD15: Metformin and dapagliflozin
A10BD21: Saxagliptin and dapagliflozin
A10BD25: Metformin, saxagliptin and dapagliflozin
A10BK: Sodium-glucose co-transporter 2 (sglt2) inhibitors
A10BK01: Dapagliflozin
HCPCS
No data
Clinical
Clinical Trials
389 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E112414577417182
Heart failureD006333EFO_0003144I501101214337
Type 1 diabetes mellitusD003922EFO_0001359E1066102123
Chronic renal insufficiencyD051436N1831032118
Diabetes mellitusD003920EFO_0000400E08-E131134110
ObesityD009765EFO_0001073E66.922318
Prediabetic stateD011236EFO_1001121R73.032247
Cardiovascular diseasesD002318EFO_0000319I9813216
Myocardial infarctionD009203EFO_0000612I2111215
HypertensionD006973EFO_0000537I10134
Show 42 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Metabolic syndromeD024821EFO_0000195E88.81233
Renal insufficiencyD051437HP_0000083N19123
Inferior wall myocardial infarctionD056989EFO_1000983112
Covid-19D000086382U07.1122
Polycystic ovary syndromeD011085EFO_0000660E28.222
Cognitive dysfunctionD060825G31.841112
Insulin resistanceD007333EFO_0002614112
Iga glomerulonephritisD005922EFO_000419411
ConfusionD003221F44.8911
Morbid obesityD009767EFO_0001074111
Show 10 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CystinuriaD003555E72.0122
Weight lossD015431HP_000182422
Breast neoplasmsD001943EFO_0003869C5022
Liver cirrhosisD008103EFO_0001422K74.022
Sleep apnea syndromesD012891EFO_0003877G47.311
Diastolic heart failureD054144EFO_1000899I50.3011
AgingD000375GO_0007568R41.81111
CardiomyopathiesD009202EFO_0000318I4211
Heart disease risk factorsD00008274211
Alzheimer diseaseD000544EFO_0000249F03111
Show 11 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients1717
Catheter ablationD01711511
Pancreatic neoplasmsD010190EFO_0003860C2511
Diabetic ketoacidosisD016883EFO_100089711
Therapeutic equivalencyD01381011
Prostatic neoplasmsD011471C6111
Reperfusion injuryD01542711
Vascular ringD000073872Q25.4511
Brain neoplasmsD001932EFO_0003833C7111
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Urinary tract infectionsD014552EFO_0003103N39.011
Unstable anginaD000789EFO_1000985I20.011
Diabetic cardiomyopathiesD058065EFO_100145811
Left ventricular dysfunctionD01848711
St elevation myocardial infarctionD00007265711
Tricuspid valve insufficiencyD014262HP_000518011
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDAPAGLIFLOZIN
INNdapagliflozin
Description
Dapagliflozin is a C-glycosyl comprising beta-D-glucose in which the anomeric hydroxy group is replaced by a 4-chloro-3-(4-ethoxybenzyl)phenyl group. Used (in the formo f its propanediol monohydrate) to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes. It has a role as a hypoglycemic agent and a sodium-glucose transport protein subtype 2 inhibitor. It is a C-glycosyl compound, an organochlorine compound and an aromatic ether.
Classification
Small molecule
Drug classphlorozin derivatives, phenolic glycosides
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1
Identifiers
PDB
CAS-ID461432-26-8
RxCUI1488564
ChEMBL IDCHEMBL429910
ChEBI ID85078
PubChem CID9887712
DrugBankDB06292
UNII ID1ULL0QJ8UC (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
SLC5A1
SLC5A1
SLC5A2
SLC5A2
Organism
Homo sapiens
Gene name
SLC5A1
Gene synonyms
NAGT, SGLT1
NCBI Gene ID
Protein name
sodium/glucose cotransporter 1
Protein synonyms
High affinity sodium-glucose cotransporter, Na+/glucose cotransporter 1, solute carrier family 5 (sodium/glucose cotransporter), member 1, Solute carrier family 5 member 1
Uniprot ID
Mouse ortholog
Slc5a1 (20537)
sodium/glucose cotransporter 1 (Q8C3K6)
Variants
Clinical Variant
No data
Financial
Forxiga - Bristol Myers Squibb
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Qtern - AstraZeneca
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Farxiga - AstraZeneca
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 8,617 documents
View more details
Safety
Black-box Warning
Black-box warning for: Xigduo
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
26 adverse events reported
View more details